We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App





AITbiotech Exhibits abTES Molecular Diagnostics Assays at MEDLAB 2017

By LabMedica International staff writers
Posted on 09 Feb 2017
Print article
Image: The abTES Flu 4 qPCR VII test kit (Photo courtesy of AITbiotech).
Image: The abTES Flu 4 qPCR VII test kit (Photo courtesy of AITbiotech).
AITbiotech Pte Ltd., a Singapore-based genomic service and molecular diagnostics (MDx) company, exhibited its comprehensive range of abTES MDx assays, including its newly launched Zika assays and the multiplex respiratory panel, at MEDLAB 2017, the world’s largest laboratory exhibition and congress in the Middle East.

AITbiotech provides a complete suite of genomic services, including capillary sequencing, next-generation sequencing services, bioinformatics services and customized molecular services, to the research, healthcare and biomedical industries in Singapore and Asia. The company also manufactures and distributes its own line of real-time PCR pathogen detection assays branded as abTES in the Asian and European markets.

At MEDLAB 2017, held at the Dubai International Convention & Exhibition Centre, UAE, from February 6-9, 2017, AITbiotech showcased its abTES MDx range of assays, which uses real-time PCR (qPCR) technology to offer unsurpassed sensitivity and specificity, thus allowing for accurate detection of pathogens within hours. AITbiotech’s assays with internal control for simultaneous detection and differentiation of infectious pathogens are compatible with various platforms. Its timesaving and user-oriented protocols ensure fast turnaround time, from sample to results in 3.5 hours.

Alex Thian, CEO of AITbiotech, said, “We are excited to be part of this premier exhibition. After many years of development of our assays and focusing in the Asia Pacific market, we are finally are able to expand to more markets. We believe that Middle East will be the best market for us to expand into, primarily due to the relevance of our abTES assay offerings to the needs of the Middle East Market. We are looking for local partners to work with us collaboratively to introduce our abTES MDx assays to the Middle East market.”

New
Gold Supplier
SARS-CoV-2 Assay
INgezim COVID 19 SPIKE CROM
New
1,5-AG Test
1,5-Anhydroglucitol Test Kit
New
Automated Immunoassay Analyzer
cobas e 411
New
STI Test
Rheonix STI TriPlex Assay

Print article
IIR Middle East

Channels

Molecular Diagnostics

view channel
Image: Metabolomic profiling reveals risk of multiple diseases all at once (Photo courtesy of BIH)

Single Blood Test Predicts Risk of Multiple Diseases Simultaneously Using AI

Prevention is better than cure. To prevent diseases from occurring in the first place, it is important to identify those individuals who are at particularly high risk as early as possible.... Read more

Technology

view channel
Image: OneDraw Blood Collection Device significantly reduces obstacles for drawing blood (Photo courtesy of Drawbridge Health)

Near Pain-Free Blood Collection Technology Enables High-Quality Testing

Blood tests help doctors diagnose diseases and conditions such as cancer, diabetes, anemia, and coronary heart disease, as well as evaluate organ functionality. They can also be used to identify disease... Read more

Industry

view channel
Image: The MC-80 digital cell morphology analyzer can screen and diagnose malignant and non-malignant blood diseases (Photo courtesy of Mindray)

Mindray Showcases Hematology Innovations at ISLH 2022

Mindray (Shenzhen, China) showcased its hematology innovations and academic achievements to medical experts from Europe and around the world at the International Symposium on Technological Innovations... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.